Atlantis Healthcare: Addressing the 'why' behind treatment nonadherence
community download

Atlantis Healthcare: Addressing the 'why' behind treatment nonadherence

information we require

please check before submitting



Privacy statement »

Manage your email preferences »

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

Self-management and support solutions for patients with rare disease need to target the real reasons why they don’t follow prescribed treatment.

 

Learn how health psychology can change the face of non adherence at Atlantis Healthcare at World Orphan Drug Congress USA 2016.

 

Atlantis Healthcare will be hosting a workshop on April 20 "Addressing the ‘why’ behind nonadherence: leveraging health psychology to design effective interventions in rare disease".

 

Adherence is an issue that is relevant for many stakeholders within pharma. This workshop is particularly suitable for brand/product director/managers, patient engagement/insights specialists, patient adherence center of excellence leads, medical science liaisons and internal market research/analytic teams.

 

By attending this course, you will learn how the application of health psychology can drive a more effective way of understanding beliefs that drive behaviors in a target population, and how to leverage those insights to develop a more relevant and effective set of interventions.

 

Topics to be covered:

  • Conceptualizing treatment non adherence - what is it, how common is it, why is it a problem, and how do we measure it?
  • Reasons for treatment non adherence - applying psychological models to understand drivers behind non adherent behaviors
  • Developing interventions to enhance adherence - what are the key characteristics of successful interventions, and how can pharma apply these to patients living with rare disease
  • Deploying adherence interventions within market and regulatory constraints - key considerations for pharma.